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Abstract
Aberrant receptor kinase signalling and tumour neovascularization are hallmarks of medulloblastoma development and are both considered valu-
able therapeutic targets. In addition to VEGFR1/2, expression of PDGFR a/b in particular has been documented as characteristic of metastatic dis-
ease correlating with poor prognosis. Therefore, we have been suggested that the clinically approved multi-kinase angiogenesis inhibitor Axitinib,
which specifically targets these kinases, might constitute a promising option for medulloblastoma treatment. Indeed, our results delineate anti-
neoplastic activity of Axitinib in medulloblastoma cell lines modelling the most aggressive c-myc-amplified Non-WNT/Non-SHH and SHH-TP53-
mutated tumours. Exposure of medulloblastoma cell lines to Axitinib results in marked inhibition of proliferation and profound induction of cell
death. The differential efficacy of Axitinib is in line with target expression of medulloblastoma cells identifying VEGFR 1/2, PDGFR a/b and c-kit as
potential markers for drug application. The high specificity of Axitinib and the consequential low impact on the haematopoietic and immune sys-
tem render this drug ideal multi-modal treatment approaches. In this context, we demonstrate that the clinically available PI3K inhibitor GDC-
0941 enhances the anti-neoplastic efficacy of Axitinib against c-myc-amplified medulloblastoma. Our findings provide a rational to further evaluate
Axitinib alone and in combination with other therapeutic agents for the treatment of most aggressive medulloblastoma subtypes.
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Introduction
Medulloblastoma is the most common malignant brain tumour of
childhood. Despite current intensive therapy including a combination
of surgery, chemotherapy and radiation, still one-third of the patients
succumb to this disease [1]. Thus, novel treatment modalities are
urgently needed.
Signalling via vascular endothelial growth factor receptor VEGFR
1/2, platelet-derived growth factor receptor a/b (PDGFR a/b) and
c-kit is critical for medulloblastoma development and progression
[2–7]. Axitinib, a potent angiogenesis inhibitor specifically targets
these kinases with high affinity [8].
Axitinib has been approved by the Food and Drug Administration
for the treatment of advanced renal cell carcinoma [8]. Multiple phase
I, II and III studies in adult patients suffering from various cancers
including glioblastoma multiforme document the efficacy and good
tolerability of Axitinib [9, 10]. In comparison with broad-spectrum
multi-kinase inhibitors such as Sorafenib and Sunitinib, the high
specificity of Axitinib and the documented favourable toxicity profile,
in particular, with respect to haematologic adverse events, render this
drug an ideal candidate for complementation of immunotherapy,
chemotherapy and other targeted agents [11–14].
While the anti-angiogenic capacity of Axitinib has been extensively
delineated, only few reports show that the anti-tumour activity of Axi-
tinib is also mediated by inhibition of its target kinases VEGFR1-3,
PDGFR a/b and c-kit expressed by the tumour cells themselves [15–
20]. In medulloblastoma, aberrant activation of these receptor tyrosine
kinases (RTKs) is considered key to tumour development and progres-
sion [2–4, 6, 7, 21]. PDGFR a and b expression, in particular, have
been found to be characteristic of metastatic disease and correlates
with poor prognosis [5, 6]. In a xenograft mouse model, we previously
documented tumour regression and prolonged survival following
treatment of orthotopic medulloblastoma with the broad spectrum
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multi-kinase inhibitors Pazopanib and Sorafenib [22]. In comparison
with these drugs, Axitinib exhibits an exceedingly low IC50 for the
mentioned RTKs such that it recommends itself as a highly attractive
agent especially for multi-modal treatment approaches [8, 23]. To
date, Axitinib has been successfully incorporated into the treatment
regimes of adult malignancies [8, 9]. However, studies evaluating its
efficacy in paediatric tumour entities are lacking.
Here, we report that Axitinib displays anti-proliferative, anti-clono-
genic and pro-apoptotic activity in cell lines modelling the most
aggressive c-myc-amplified Non-WNT/Non-SHH and SHH-TP53-
mutated medulloblastoma variants associated with a very poor prog-
nosis [24–30]. In line with these findings, we demonstrate that Axitinib
treatment reduces the phosphorylation state of the signalling mole-
cules AKT and signal transducer and activator of transcription 3
(STAT3) known to be downstream of the targeted kinases VEGFR1/2,
PDGFR a/b and c-kit. Recently, our research group documented
in vitro and in vivo the anti-neoplastic potential of the phosphoinositid-
3-kinase (PI3K) inhibitor GDC-0941 for medulloblastoma therapy [31].
Here, we show that Axitinib in combination with GDC-0941 displays
enhanced cytotoxic and anti-proliferative efficacy alongside with a
complete abrogation of AKT and STAT3 signalling in c-myc-amplified
medulloblastoma. Thus, our data provide a rational for further assess-
ment of Axitinib alone and in combination with other therapeutic
approaches such as PI3K inhibitors for medulloblastoma treatment.
Material and methods
Reagents and antibodies
Axitinib and GDC-0941 were obtained from LC Laboratories (Woburn,
MA, USA). The primary antibodies pSTAT3 (TYR705, D3A7), STAT3
(124H6), pAKT (Ser473), AKT (11E7) and GAPDH were purchased from
Cell Signalling while secondary antibodies were purchased from Dianova
(Hamburg, Germany). Carboxyfluoreszein-succinimidyl ester (CFSE) was
purchased from Invitrogen (Carlsbad, CA, USA), while Hoechst 33258
was provided by Sigma-Aldrich (St. Louis, MO, USA).
Cell culture
The human medulloblastoma cell lines Daoy (HTB 186) and D283 Med
(HTB-185) were obtained from American Type Culture Collection
(ATCC). The medulloblastoma cell line MEB-Med-8A was generated by
Prof. T. Pietsch. The medulloblastoma cell lines Daoy, D283 Med and
MEB-Med-8A were maintained in complete medium, namely Dulbecco’s
modified Eagle’s medium (DMEM, PAA), with L-glutamine supplemented
with 1 mM sodium pyruvate (PAA), 1% penicilline/streptomycine (Invit-
rogen) and 10% foetal bovine serum (FBS, Invitrogen).
Quantification of cell numbers
MEB-Med-8A (7 9 105), D283 Med (5 9 105) and Daoy (3 9 105)
cells were seeded in 6-well cell culture dishes in complete medium.
After overnight cultivation, the cells were treated with the respective
drug concentration for 24 and 48 hrs. Dimethylsulfoxid (DMSO)
served as control. Thereafter, dead and living cells were harvested
and resuspended in an equal volume of PBS. Dead cells were identi-
fied by trypan blue stain according to the supplier’s instructions.
Results of microscopic cell count by means of a haemocytometer
were confirmed by a flow cytometric analysis. Dead cells were
excluded from analysis by Hoechst33258 stain. For each sample, the
total number of living cells measured within 100 sec. was
determined.
Cell proliferation and cell death assay
Medulloblastoma cells were stained with CFSE according to the sup-
plier’s instructions. MEB-Med-8A (7 9 105) and D283 Med (5 9 105)
and Daoy (3 9 105) cells were seeded in 6-well cell culture dishes in
complete medium. After overnight cultivation, the cells were treated
with respective concentrations of Axitinib and GDC-0941 for 48 hrs.
Thereafter, floating and attached cells were collected, stained with
Hoechst33258 and analysed by flow cytometry. Proliferation was traced
by CFSE staining and normalized to the control DMSO, while dead cell
was determined by Hoechst33258 staining.
Colony formation assay
The cell lines Daoy (200 cells/well) and MEB-Med-8A (1000 cells/well)
were plated in 6-well cell culture dishes. The cells were allowed to
adhere and spread properly for 12 hrs at 37°C. Thereafter, the cells
were exposed to the stated concentration of Axitinib. After 48 hrs of
exposure, the cells were washed with standard medium to remove any
trace of the inhibitor and cultured for another week. Colony numbers
and colony size were assessed by IMAGEJ. Particles smaller than 40
pixel2 were excluded from the analysis as these represented stain arte-
facts, cell detritus or non-proliferating single cells.
Immunoblotting analysis
The medulloblastoma cell lines Daoy, MEB-Med-8A, D283 Med and
D341 were exposed to different Axitinib concentrations for 1 and
48 hrs, respectively. Thereafter, the cells were harvested and subse-
quently lysed in RIPA buffer (Sigma-Aldrich) containing protease and
phosphatase inhibitors (protease inhibitor and PhosSTOP phos-
phatase inhibitor cocktail; Roche (Rotkreuz, Switzerland)). The lysates
were centrifuged 10 min. at 10,000 9 g, and the protein concentra-
tion was determined by means of the Bradford assay. During the
entire procedure, cells and lysates, respectively, were kept at 4°C. A
total protein concentration of 25 lg derived from medulloblastoma
cell lines was separated by SDS-polyacrylamide gel electrophoresis
and transferred to nitrocellulose membranes (Bio-Rad, Hercules, CA,
USA). The membranes were blocked for 1 hr at RT in 19 Tris-buf-
fered saline containing 0.1% tween-20 (TBST) supplemented with 5%
BSA. Thereafter, the membranes were incubated with the primary
antibodies (1/1000) overnight at 4°C and subsequently with the
respective secondary antibody (1/10,000) for 1 hr at room tempera-
ture. Immunoreactivity was detected by chemiluminescence and
quantified by means of a ChemiDoc XRS Imaging System (Bio-Rad).
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Statistical analysis
The two-sided Student’s t-test was applied to determine statistical sig-
nificance of differences between groups. P < 0.05 (*) was considered
as statistically significant. Values stated within text and figures repre-
sent mean  standard deviation.
Results
Axitinib reduces the viability of different
medulloblastoma cell lines in a time- and dose-
dependent manner
For our analysis, we chose the paediatric medulloblastoma cell
lines MEB-Med-8A, D283 Med and Daoy. MEB-Med-8A and D283
Med display distinct characteristics of c-myc-amplified Non-WNT/
Non-SHH medulloblastoma while the third analysed cell line, Daoy,
shows markers of a subgroup of SHH tumours characterized by a
mutation of tumoursuppressor protein 53 [24–30]. Cells were cul-
tured in the presence of increasing concentrations of Axitinib or the
vehicle DMSO as control with in vitro concentrations of 0.5 and
1 lM Axitinib corresponding to plasma levels observed in patients
(Fig. 1). At 24 hrs, medulloblastoma cell lines have started to pro-
liferate. At this early time, in culture, in the presence of 0.5 and
1 lM Axitinib, cell growth is significantly attenuated in MEB-Med-
8A, D283 Med in comparison with the untreated control while in
Daoy, this effect is observed only after dose escalation to 2 lM
Axitinib. In contrast, after 48 hrs, all three investigated cell lines
exhibit a significant dose-dependent reduction of viable cells in
comparison with the untreated control with a decrease in viable cell
number to 53  11% at 0.5 lM, 27  5% at 1 lM and 8  2%
at 2 lM Axitinib in MEB-Med-8A and 58  7%, 21  4% and
16  1.5% in D283 Med, respectively. In Daoy, suppression of
viable cell number is again less pronounced after 48 hrs at 0.5 and
1 lM Axitinib with 50  17% and 40  11% residual viable cells
compared to the untreated control and markedly enhanced cytore-
duction at 2 lM Axitinib to 4  3%.
At 48 hrs, significant reduction of viable cells in relation to the
number of seeded cells is noted in MEB-Med-8A with a cytoreductive
effect to 63  11% at 1 lM and 81  5.3% at 2 lM Axitinib and
78  11% and 60  5.3% viable cell numbers in D283 Med. In
Daoy, a net loss of viable cells was only detected after 48 hrs
exposure to 2 lM Axitinib with only 25  20% of the seeded cells
surviving.
Axitinib interferes with the clonogenicity of
medulloblastoma
Based on their different group affiliation, the medulloblastoma cell
lines MEB-Med-8A and Daoy were chosen to assess Axitinib-induced
modulation of colony formation (Fig. 2). In MEB-Med-8A, Axitinib
reduces colony number and size in a dose-dependent manner, while
in Daoy only the highest concentration exerts a significant inhibitory
effect. After exposure to 2 lM Axitinib, only 2  1 colonies grow in
MEB-Med-8A compared to 122  12 in the DMSO control. In con-
trast, 39  5 colonies are detectable in Daoy compared to 70  11
residual colonies in the untreated control. Furthermore, Axitinib treat-
ment also leads to profound reduction in colony size with 18  13p2
in MEB-Med-8A and 158  19p2 in Daoy in comparison with
122  11p2 and 376  50p2 in the respective controls.
Axitinib alone and in combination with the PI3K
inhibitor GDC-0941 abrogates STAT3 and AKT
activity
We exposed the medulloblastoma cell lines for 1 hr to 0.5, 1 and
2 lM and determined the activity of the VEGFR 1/2, PDGFR a/b and
c-kit downstream signalling molecules STAT3 and AKT (Fig. 3A). In
MEB-Med-8A and D283 Med, STAT3 phosphorylation levels remain
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Fig. 1 Axitinib reduces the viability of different medulloblatoma cell lines in a time- and dose-dependent manner. The stated medulloblastoma cell
lines were seeded and exposed to 0.5, 1 and 2 lM of Axitinib for 48 hrs. Cell viability was assessed by cell count after 24 and 48 hrs. Dead cells
were excluded from analysis by trypan blue staining. All values below an asterisk are significantly different from control (*P < 0.05). Each experi-
ment was performed in triplicates and repeated four times.
ª 2018 The Authors.
Journal of Cellular and Molecular Medicine published by John Wiley & Sons Ltd and Foundation for Cellular and Molecular Medicine.
2155
J. Cell. Mol. Med. Vol 22, No 4, 2018
stable comparable to controls after 1 hr of exposure to 0.5–2 lM Axi-
tinib, while in Daoy, phosphorylation levels are reduced. AKT activity,
in contrast, was significantly increased upon drug treatment in all
investigated cell lines in a dose-dependent manner.
Furthermore, 48 hrs treatment with 2 lM Axitinib moderate
reduction in STAT3 and AKT phosphorylation is observed in all anal-
ysed cell lines (Fig. 3B). Treatment with the PI3K/AKT pathway inhibi-
tor GDC-0941 alone leads to moderate reduction of STAT3 activity in
MEB-Med-8A and Daoy and profound impairment in D283 Med. GDC-
0941 also results in complete abrogation of AKT signalling in all cell
lines that is therefore not further enhanced by Axitinib. However, with
regards to AKT protein levels, combination of Axitinib and GDC-0941
does have an additive suppressive effect in MEB-Med-8A and Daoy.
The combination of Axitinib and GDC-0941 also results in decrease of
STAT3 activity in MEB-Med-8A and Daoy compared to single drug
application. Of note, the suppressive effect on STAT3 protein expres-
sion is also additive.
The PI3K inhibitor GDC-0941 enhances the anti-
neoplastic efficacy of Axitinib against c-myc-
amplified medulloblastoma
We previously showed that the clinically available PI3K inhibitor GDC-
0941 exerts significant anti-neoplastic efficacy against medulloblas-
toma in vitro and in vivo and displays additive anti-tumourigenic
efficacy with the multi-kinase inhibitor (MKI) Vandetanib [31, 32]. Here,
we investigated whether the PI3K inhibitor GDC-0941 also enhances
the pro-apoptotic and anti-proliferative activity of Axitinib. For this pur-
pose, we exposed the medulloblastoma lines for 48 hrs to 0.5–2 lM
Axitinib in combination with 1 lM GDC-0941. Cells were analysed and
enumerated by flow cytometry following a combined CFSE-
Hoechst33258 stain. The vehicle DMSO served as control (Fig. 4).
In the c-myc-amplified Non-WNT/Non-SHH medulloblastoma
lines MEB-Med-8A and D283 Med, Axitinib reduces viable cell number
Fig. 2 Axitinib interferes with the clonogenicity of medulloblastoma. Daoy and MEB-Med-8A cells were exposed to 0.5, 1 and 2 lM Axitinib for
48 hrs. Subsequently, the cells were maintained in standard growth medium for 7 days and colony formation and colony size were assessed. Statis-
tically significant differences from control are marked by an asterisk (*P < 0.05). The data shown represent five independent experiments.
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in a dose-dependent manner starting at the lowest concentration of
0.5 lM, while in the SHH-TP53-mutated cell line Daoy, a significant
decrease was only observed at 2 lM, the highest concentration
applied. In both the c-myc-amplified Non-WNT/Non-SHH medul-
loblastoma cell lines, an additive cytoreductive effect of GDC-0941 is
noticeable when combined with 1 and 2 lM Axitinib.
After treatment of MEB-Med-8A and D283 Med with 1 lM Axi-
tinib, a decline to 39  5% and 36  5% residual viable cells is
observed, respectively, while after exposure to 1 lM GDC-0941,
19  1.6% and 47  5% cells survive. Compared to either drug
alone, the combination of 1 lM Axitinib with 1 lM GDC-0941 sig-
nificantly decreases the number of viable cells to 3.6  1% in
MEB-Med-8A and to 14  3% in D283 Med. In MEB-Med-8A, cell
loss was complete after combined exposure to 2 lM Axitinib and
1 lM GDC-0941. Yet, in D283 Med, there was no further loss in
viable cell number. Daoy, in contrast, is considerably more resis-
tant to Axitinib. Viable Daoy cells are 90  22 and 91  19% at
concentrations of at 0.5 lM and 1 lM Axitinib. Notably, cytoreduc-
tive activity is documented at 2 lM Axitinib with 30  2.5% cell
surviving, which is significantly lower than after exposure to 1 lM
GDC-0941 alone but without any additional effect by the drug com-
bination.
We further dissected the anti-neoplastic effect of Axitinib with
regards to its pro-apoptotic and anti-proliferative capacity based on
the combined CFSE-Hoechst33258 stain. There was a substantial cell
death effect upon escalation of Axitinib from 1 to 2 lM. After treat-
ment with 2 lM Axitinib, 75  4% of dead cells were detected in
MEB-Med-8A and 36  3% in Daoy. In MEB-Med-8A and Daoy, this
exceeds the cell death observed with 1 lM GDC-0941 resulting in
40  3.5% and 9  4% cell death, respectively. Compared to single
drug application, the Axitinib-GDC-0941 combination significantly
enhances cytotoxicity in MEB-Med-8A for all Axitinib concentrations,
while in Daoy, dose escalation of Axitinib had the major cytotoxic
effect. In D283 Med, increasing the Axitinib dose has no effect on cell
death, which remains below 20% as is the case with 1 lM GDC-0941
alone. However, in combination with GDC-0941, cytotoxicity is twice
as pronounced reaching 43  10% and 37  8% when coadminis-
tered with 1 and 2 lM Axitinib, respectively. Moreover, AnnexinV/
7ADD staining reveals that Axitinib alone or in combination with GDC-
0941 exerts a pro-apoptotic effect on all three medulloblastoma cell
lines (Fig. S3).
With regards to the anti-proliferative activity, in MEB-Med-8A and
Daoy, the most prominent effect is achieved with 2 lM Axitinib alone
compared to all other experimental conditions with 57  3.5% and
43  1.5% of growth inhibition, respectively. At lower Axitinib con-
centrations, the combination with GDC-0941 augmented the anti-pro-
liferative effect in MEB-Med-8A and D283 Med compared to single
Axitinib application at the respective concentration. However, there
was no additional effect compared to GDC-0941 alone in MEB-Med-
8A and Daoy.
Fig. 3 Axitinib alone and in combination
with the phosphoinositid-3-kinase (PI3K)
inhibitor GDC-0941 affects signal trans-
ducer and activator of transcription 3
(STAT3) and AKT signalling. Daoy, MEB-
Med-8A and D283 Med cells were treated
for 1 hr with 0.5, 1 and 2 lM (A) and for
48 hrs with 2 lM of Axitinib (B), respec-
tively. Furthermore, the stated medul-
loblastoma cell lines were exposed for
48 hrs to 2 lM Axitinib in the presence of
1 lM GDC-0941 (B). Total protein levels
and phosphorylation status of AKT and
STAT3 were determined by Western blot.
GAPDH served as loading control.
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Discussion
To date, targeted therapies have become an integral element of can-
cer treatment [33]. Multi-kinase inhibitors with anti-angiogenic prop-
erties also directly impair signal transduction pathways critical for
neoplastic transformation and tumour progression. The availability of
anti-cancer drugs with partially redundant target profiles such as Van-
detanib, Sorafenib, Sunitinib and Pazopanib is steadily increasing
[34]. Axitinib stands out from these broad-spectrum MKI, as it dis-
plays one to two log higher affinity to the receptors for VEGFR1-3,
PDGFR a/b and c-kit with a favourable toxicity profile that renders
Axitinib well suited for combination therapy with other targeted
agents [8].
While Axitinib is currently under clinical investigation in glioblas-
toma, this is a first report documenting profound anti-neoplastic
activity in paediatric medulloblastoma cell lines [10]. In MEB-Med-8A
and D283 Med with specific characteristics of the most aggressive c-
myc-amplified Non-WNT/Non-SHH medulloblastoma variant [24–29],
Axitinib reduces viable cell number in a dose-dependent manner with
the highest responsiveness in MEB-Med-8A. Of the three medul-
loblastoma cell lines assessed, MEB-Med-8A is the only cell line that
does not express cancer stem cell markers (Fig. S1). At the highest
dose, significant cytoreductive activity is also achieved in Daoy repre-
senting the TP53-mutated subgroup of SHH tumours with extremely
poor survival rates [30]. The observation that the SHH-TP53-mutated
cell line—Daoy—is less susceptible to lower doses of Axitinib might
DaoyMEB-Med-8A D283 Med
0
20
40
60
80
100
— +
+Axit.0.5 +Axit. 1 +Axit. 2
— + — +
GDC-0941
1 µM
C
el
ld
ea
th
(%
)
+0
20
40
60
80
100
C
el
ld
ea
th
(%
)
— +
+Axit.0.5 +Axit. 1 +Axit. 2
Co
ntr
ol
Co
ntr
ol
Co
ntr
ol— + — + GDC-0941
+
*
* *
0
20
40
60
80
100
GDC-0941
1 µM1 µM
— +
+Axit.0.5 +Axit. 1 +Axit. 2
— + — +
C
el
ld
ea
th
(%
)
+
* *
0
5
10
15
20
25
30 Without GDC
With GDC
Ax
it.0
.5
Ax
it.
1
Ax
it.
2
Co
ntr
ol
Vi
ab
le
ce
lls
x
1 0
3
Vi
ab
le
ce
lls
x
1 0
3
Vi
ab
le
ce
lls
x
1 0
3
0
40
80
120
160
Ax
it.0
.5
Ax
it.
1
Ax
it.
2
Co
ntr
ol
GDC—0941
1 µM
*
*
*
0
20
40
60
80
Ax
it.0
.5
Ax
it.
1
Ax
it.
2
Co
ntr
ol
*
*
* *
0
10
20
30
40
50
+Axit.0.5 +Axit. 1 +Axit. 2 GDC-0941
1 µM
— + — + — +
In
hi
bi
tio
n
of
pr
ol
ife
ra
ti o
n
(%
)
no
rm
al
iz
ed
w
ith
D
M
SO
+
*
+Axit.0.5 +Axit. 1 +Axit. 2
— + — + — +
GDC-0941
0
10
20
30
40
50
+
*
*
In
hi
bi
tio
n
of
pr
ol
ife
ra
tio
n
(%
)
no
rm
al
iz
ed
w
ith
D
M
SO
+Axit.0.5 +Axit. 1 +Axit. 2
—— + — + +
GDC-0941
1 µM 1 µM
0
10
20
30
40
50
60
70
+
*
In
hi
bi
tio
n
of
pr
ol
ife
ra
tio
n
(%
)
no
rm
al
iz
ed
w
ith
D
M
SO
#
#
*
#
#
#
#
#
#
#
#
#
# #
GDC-0941
1 µM
GDC-0941
1 µM
A
B
C
Fig. 4 The phosphoinositid-3-kinase (PI3K) inhibitor GDC-0941 enhances the anti-neoplastic efficacy of Axitinib against c-myc-amplified medulloblas-
toma. The cells were treated with the stated concentrations of Axitinib alone and in combination with 1 lM of GDC-0941. In a combined flow cyto-
metric cell viability/proliferation assay based on a carboxyfluoreszein-succinimidyl ester (CFSE)/Hoechst 33258 stain, (A) the total number of viable
cells as number of events acquired in 100 sec. and (B) the percentage of dead cells (Hoechst33258+ cells) were assessed by flow cytometry after
48 hrs of treatment. (C) Inhibition of proliferation, traced by CFSE staining, was normalized to the control dimethylsulfoxid (DMSO) and all stated
values differ significantly (P < 0.05) from the control DMSO. Statistically significant differences between Axitinib single application and the Axitinib-
GDC combination are marked with an asterisk, while statistically significant differences between GDC-0941 and the Axitinib-GDC combination are
marked by a hash sign (#P < 0.05). The dot line in A represents the number of viable cells upon treatment with 1 lM of GDC-0941 only for
48 hrs. The data shown represent four independent experiments.
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also reflect the fact that Daoy differs in its target profile from the
myc-amplified medulloblastoma lines MEB-Med-8A and D283 Med
with similar VEGFR1-3, PDGFR a/b receptor but lower levels of c-kit
receptor expression (Table S1).
The profound loss of cell viability in all three MB lines can be
attributed to marked pro-apoptotic and anti-proliferative activity. Axi-
tinib arrests proliferation in G2/M phase (Fig. S2) and interferes with
medulloblastoma clonogenicity regardless of medulloblastoma group
affiliation.
In clinical pharmacokinetic studies, there is a high degree of vari-
ability in plasma levels even in healthy volunteers. However,
although it is well documented that Axitinib is primarily metabolized
by CYP3A4/5 and to a lesser extent by CYP1A2, CYP2C19 and
UGT1A1, in two meta-analyses, no association between plasma
levels and polymorphisms of these enzymes was found. [35, 36] In
clinical anti-cancer therapy, daily doses range from 10 to 20 mg Axi-
tinib depending on the sensitivity to adverse events and anti-neo-
plastic efficacy in the respective patient cohorts. Thus, in renal cell
carcinoma patients, plasma levels range between 0.5 and 1 lM fol-
lowing administration of 20 mg of Axitinib [37]. Within the range of
0.5 and 1 lM, our in vitro experiments proof anti-neoplastic efficacy
against different medulloblastoma cell lines. Morover, in vivo, drug
accumulation or retention as a result of newly formed dysfunctional
tumour vessels might lead to spatial Axitinib concentration in the
brain tumour tissue that exceeds the patient plasma concentration
[38]. Thus, in vivo, in addition to direct anti-tumour effects, modula-
tion of the tumour microenvironment contributes to MKI efficacy.
Thus, a recent report on a phase II clinical study in recurrent
glioblastoma concludes that Axitinib improves response and pro-
gression-free survival [10]. Two additional phase II clinical trials
testing the efficacy and safety of Axitinib in patients with glioblas-
toma are currently under way. (ClinicalTrials.gov Identifier:
NCT03291314 and NCT01508117).
In medulloblastoma, we have previously shown in an orthotopic
in vivo xenograft model that the oral administration of the broad-
spectrum MKI Sorafenib and Pazopanib attenuate tumour growth and
prolong survival [22], an effect that was significantly enhanced by the
addition of the PI3K inhibitor GDC-0491 [31]. Based on the promising
in vitro cytotoxicity of Axitinib shown here further in vivo studies eval-
uating Axitinib in orthotopic medulloblastoma mouse models are war-
ranted. Pazopanib and Sorafenib also target VEGFR1-3, PDGFR a/b
and c-kit among other kinases and affect medulloblastoma prolifera-
tion and cell survival by inhibition of STAT3 and, to a lesser extend,
AKT phosphorylation [22, 39, 40]. These observations underline the
importance of the respective signalling elements in aberrant RTK acti-
vation in medulloblastoma and provide evidence of significant cross-
talk between these pathways [31]. While prolonged treatment with
the highly specific MKI Axitinib impairs both STAT3 as well as AKT
activity in MEB-Med-8A and Daoy, after 1 hr of drug exposure, tran-
sient albeit profound upregulation of AKT activation is observed. This
underscores the notion that in medulloblastoma, combined inhibition
of both signalling elements STAT3 and AKT might enhance anti-
tumour efficacy.
With acceptable tolerability including limited haemotological side
effects, Axitinib is particularly well suited for combination therapy
[14, 41]. Axitinib also has a favourable profile with respect to the anti-
tumour T cell response with less pronounced inhibitory effects on T
cell effector functions compared to other broad-spectrum MKI [42].
In solid tumours including intracerebral neoplastic lesions, Axitinib
facilitates a shift from a suppressive to an activated immunologic
milieu [43–45]. Thus, MKI-mediated effects on the haematopoietic
and immune system are of particular interest when considering
administration in conjunction not only with chemotherapy but also
with immunotherapy or other targeted agents [46–48]. Within this
context, it has recently been reported that the combination of Axitinib
with the anaplastic lymphoma kinase (ALK) inhibitor dalantercept is
well tolerated [49]. Furthermore, combined inhibition of the mTOR
pathway and AKT by Axitinib and Everolimus is momentarily under
extensive evaluation in patients with disease progression in various
solid cancers (ClinicalTrials.gov Identifier: NCT 01334073). Against
this background, we have previously shown that upstream of mTOR/
AKT the clinically available PI3K inhibitor GDC-0941 potently inhibits
AKT phosphorylation in high-risk variants of medulloblastoma and
promotes survival in an orthotopic xenograft model [31]. Here, we
demonstrate that application of GDC-0941 in combination with Axi-
tinib significantly enhances the anti-neoplastic efficacy in cell lines
harbouring a c-myc amplification compared to treatment with either
drug alone. Combination of Axitinib with the AKT inhibitor GDC-0941
results in near to complete abrogation of viable cells in MEB-Med-8A
and D283 Med. Corresponding to the enhanced cytotoxicity of the
Axitinib-GDC-0941 combination, AKT and STAT3 signalling are mark-
edly impaired. While there is a cumulative suppressive effect of Axi-
tinib and GDC-0941 on STAT3 activity, as expected the specific PI3K
inhibitor dominates the inhibitory effect on AKT. The significance of
PI3K/AKT signalling has not only been delineated for c-myc-amplified
medulloblastoma but also for cerebellar cells overexpressing c-myc
resulting in a similar molecular profile and PI3K dependency [50].
Upregulated PI3K signalling is also a feature of cancer stem cells and
corresponds to the capacity for self-renewal in a number of tumour
entities including glioblastoma [51]. In contrast to the c-myc-ampli-
fied MEB-Med-8A and D283 Med medulloblastoma cells, in the SHH-
TP53-mutated medulloblastoma line Daoy, at the highest dose, the
anti-neoplastic effect of Axitinib exceeds the cytotoxic activity of
GDC-0941 and combination of the two drugs has no additional effect.
Of note, across the different medulloblastoma entities, not only the
activity of STAT3 and AKT but also protein levels are diminished by
the applied inhibitors, which is most likely because of the role of
STAT3 and AKT as key regulators of protein expression [52, 53]. Our
previous study delineates a similar result for the MKI Vandetanib that
also targets VEGFR-2 and 3 but, in addition, the EGFR receptor. In
contrast to this study, we have previously documented that the Van-
detanib-GDC-0941 combination displayed enhanced anti-neoplastic
efficacy compared to single drug application in Daoy [32]. This might
be because of to the fact that Daoy expresses high levels of the Van-
detanib target EGFR but expression of the Axitinib target c-kit as men-
tioned above is low. This finding points towards receptor tyrosine
expression profiles as biomarker for MKI treatment.
In conclusion, our study demonstrates that Axitinib, a highly
specific clinically available inhibitor of angiogenesis, displays
marked cytotoxic activity against paediatric medulloblastoma cell
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lines modelling most aggressive c-myc-amplified Non-WNT/Non-
SHH and SHH-TP53-mutated tumours. In this setting, marked anti-
proliferative property of Axitinib is complemented by profound
cytotoxic capacity. We further show that Axitinib anti-neoplastic
efficacy correlates with the target expression profile on the tumour
cells. As the availability of anti-cancer agents with partially redun-
dant target profiles such as Axitinib, Vandetanib, Sorafenib, Suni-
tinib and Pazopanib is steadily increasing, biomarkers supporting
the choice of MKI are of increasing importance. With regards to
multi-modal treatment approaches, PI3K/AKT pathway inhibition by
means of GDC-0941 enhances the efficacy of Axitinib against
c-myc-amplified medulloblastoma. Our data suggest that Axitinib
single treatment or in combination with PI3K inhibitors such as
GDC-0941 might prove a promising strategy to clinically target the
most aggressive c-myc-amplified and SHH-TP53-mutated medul-
loblastoma subtypes.
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